The series of molecular signals initiated by a nodal protein binding of to an activin receptor on the surface of a target cell, which contributes to the establishment of an organism's body plan or part of an organism with respect to the left and right halves.

The series of molecular signals initiated by nodal protein binding to an activin receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.

The series of molecular signals initiated by leptin binding to its receptor on the surface of a cell, which reduces appetite, the desire or physical craving for food.

The series of molecular signals initiated by leptin binding to its receptor on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription. Leptin is a hormone manufactured primarily in the adipocytes of white adipose tissue, and the level of circulating leptin is directly proportional to the total amount of fat in the body.

Any process that reduces appetite.

The series of molecular signals initiated by the binding of stem cell factor to the tyrosine kinase receptor KIT on the surface of a target cell, and ending with regulation of a downstream cellular process, e.g. transcription. Stem cell factor (KIT ligand) binding to the receptor Kit mediates receptor dimerization, activation of its intrinsic tyrosine kinase activity and autophosphorylation. The activated receptor then phosphorylates various substrates, thereby activating distinct signaling cascades within the cell that trigger a change in state or activity of the cell.

Interacting with an activin receptor to reduce the action of the agonist nodal. A receptor antagonist does not initiate signaling upon binding to a receptor, but instead blocks an agonist from binding to the receptor.

Interacting with an activin receptor complex to reduce the action of another ligand, the agonist. A receptor antagonist does not initiate signaling upon binding to a receptor, but instead blocks an agonist from binding to the receptor.

A protein complex containing at least a type II activin receptor, a type I activin receptor, and a coreceptor (EGF-CFC protein) such as Cripto or Cryptic. Nodal receptor complexes are capable of binding a nodal protein and transducing the signal into the cell.

Binding to a transforming growth factor-beta (TGFbeta) protein in the extracellular region, and inhibiting TGFbeta signaling by preventing TGFbeta from binding to its cell surface receptor.

The process of binding or confining an extracellular signaling ligand, such that the ligand is unable to bind to its cell surface receptor.

Binding to choriogonadotropin hormone, a heterodimer, with an alpha subunit identical to that of luteinizing hormone (LH), follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH), and a unique beta subunit.

Binding to a nodal protein, a member of the transforming growth factor-beta superfamily.

Binding to a nodal protein in the extracellular region, and inhibiting nodal signaling by preventing nodal from binding to its cell surface receptor.

The series of molecular signals transmitted by a heterodimeric complex of the tyrosine kinase receptors ERBB3 and ERBB4. The pathway begins with binding of a ligand to either cell surface receptor, or the dimeric receptor complex, and ends with regulation of a downstream cellular process, e.g. transcription.

The series of molecular signals initiated by binding of a ligand to the tyrosine kinase receptor ERBB3 on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription. ERBB3 receptors have impaired kinase activity and rely on the kinase activity of the heterodimer partner for activation and signal transmission.

The series of molecular signals initiated by binding of a ligand to the tyrosine kinase receptor ERBB4 on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription.

The series of molecular signals transmitted by a heterodimeric complex of the tyrosine kinase receptors EGFR (epidermal growth factor receptor/ERBB1) and ERBB4. The pathway begins with binding of a ligand to either cell surface receptor, or the dimeric receptor complex, and ends with regulation of a downstream cellular process, e.g. transcription.

The series of molecular signals initiated by binding of a ligand to the tyrosine kinase receptor ERBB4, followed by ligand-induced homodimerization of ERBB4 and transmission of the signal into the cell by the homodimeric ERBB4 complex. The pathway ends with regulation of a downstream cellular process, e.g. transcription.

A heterodimeric complex between the tyrosine kinase receptors ERBB4 (also called HER4) and epidermal growth factor receptor (EGFR/ERBB1).